{"html":"<!DOCTYPE html><html><body><h4>Population pharmacokinetic parameter estimates for the typical individual after administration of cladribine as; an infusion, orally or subcutaneously. The relative standards errors are given in parentheses. The estimates of intersubject variability are given as coefficients of variation (%).</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Parameter</bold></td><td align=\"left\" colspan=\"2\"><bold>Population average</bold></td><td align=\"left\" colspan=\"2\"><bold>Interindividual variability</bold></td></tr><tr><td/><td align=\"left\">Estimate</td><td align=\"left\">(RSE%)<sup>1</sup></td><td align=\"left\">Estimate %</td><td align=\"left\">(RSE%)</td></tr></thead><tbody><tr><td align=\"left\">Clearance (L/h)</td><td align=\"left\">39.3</td><td align=\"left\">(4.9)</td><td align=\"left\">54</td><td align=\"left\">(17)</td></tr><tr><td align=\"left\">V1 (L)</td><td align=\"left\">71.7</td><td align=\"left\">(13)</td><td align=\"left\">34</td><td align=\"left\">(62)</td></tr><tr><td align=\"left\">Q2 (L/h)</td><td align=\"left\">51.1</td><td align=\"left\">(6.8)</td><td align=\"left\">61</td><td align=\"left\">(17)</td></tr><tr><td align=\"left\">V2 (L)</td><td align=\"left\">475</td><td align=\"left\">(1.8)</td><td align=\"left\">70</td><td align=\"left\">(31)</td></tr><tr><td align=\"left\">Q3 (L/h)</td><td align=\"left\">105</td><td align=\"left\">(21)</td><td align=\"left\">61</td><td align=\"left\">(17)</td></tr><tr><td align=\"left\">V3 (L)</td><td align=\"left\">73.6</td><td align=\"left\">(13)</td><td align=\"left\">61</td><td align=\"left\">(17)</td></tr><tr><td align=\"left\">Oral Ka (h<sup>-1</sup>)</td><td align=\"left\">1.31</td><td align=\"left\">(14)</td><td align=\"left\">75</td><td align=\"left\">(50)</td></tr><tr><td align=\"left\">Oral F</td><td align=\"left\">0.353</td><td align=\"left\">(7.9)</td><td align=\"left\">4.1</td><td align=\"left\">(63)</td></tr><tr><td align=\"left\">Subcutaneous Ka (h<sup>-1</sup>)</td><td align=\"left\">2.48</td><td align=\"left\">(9,6)</td><td align=\"left\">N.E.</td><td/></tr><tr><td/><td/><td/><td/><td/></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Parameter</bold></td><td align=\"left\"><bold>Infusion (RSE %)</bold></td><td align=\"left\"><bold>Oral (RSE %)</bold></td><td align=\"left\"><bold>Subcutaneous (RSE %)</bold></td><td align=\"left\"><bold>IIV<sup>3 </sup>(RSE %)</bold></td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\">Residual error<sup>2</sup></td><td/><td/><td/><td/></tr><tr><td align=\"left\">Proportional</td><td align=\"left\">0.191 (8.2)</td><td align=\"left\">0.232(9.8)</td><td align=\"left\">0.162 (8.8)</td><td align=\"left\">24 (28)</td></tr></tbody></table></body></html>","text":"Pmid= 1079880:Table= Table 3","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":929945034,"_task_hash":59779801,"_session_id":null,"_view_id":"choice","accept":[0],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Descriptive statistics and distribution of diagnoses for patients initially included in the population pharmacokinetic analysis.</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Gender </bold>m/f</td><td align=\"left\"><bold>Age </bold>(years)<sup>2</sup></td><td align=\"left\"><bold>Weight </bold>(kg)<sup>2</sup></td><td align=\"left\"><bold>Height </bold>(cm)<sup>2</sup></td><td align=\"left\"><bold>BSA</bold><sup>1 </sup>(m<sup>2</sup>)<sup>2</sup></td><td/></tr></thead><tbody><tr><td align=\"left\"><bold>Total</bold></td><td align=\"left\">129/34</td><td align=\"left\">60 (13) [22\u201389]</td><td align=\"left\">76 (14) [48\u2013118]</td><td align=\"left\">174 (9) [152\u2013198]</td><td align=\"left\">1.9 (0.2) [1.5\u20132.4]</td><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align=\"left\"><bold>Diagnosis</bold></td><td align=\"left\"><bold>CLL</bold></td><td align=\"left\"><bold>HCL</bold></td><td align=\"left\"><bold>AML</bold></td><td align=\"left\"><bold>NHL</bold></td><td align=\"left\"><bold>CML</bold></td><td align=\"left\"><bold>LCH</bold></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"left\">63</td><td align=\"left\">84</td><td align=\"left\">3</td><td align=\"left\">7</td><td align=\"left\">4</td><td align=\"left\">2</td></tr></tbody></table></body></html>","text":"Pmid= 1079880:Table= Table 1","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-664711252,"_task_hash":1069409488,"_session_id":null,"_view_id":"choice","accept":[1],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Distribution of laboratory data for patients included in the population pharmacokinetic analysis</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td/><td align=\"left\"><bold>Mean</bold></td><td align=\"left\"><bold>SD</bold></td><td align=\"left\"><bold>Range</bold></td><td align=\"left\"><bold>Outliers</bold></td></tr></thead><tbody><tr><td align=\"left\">Creatinine clearance (mL/min)</td><td align=\"left\">81</td><td align=\"left\">27</td><td align=\"left\">5\u2013162</td><td align=\"left\">5<sup>i</sup>, 16<sup>i</sup>, 27<sup>i</sup>, 161<sup>sc</sup>, 162<sup>i, o</sup></td></tr><tr><td align=\"left\">S-aspartate aminotransferase (\u03bckat/L)</td><td align=\"left\">0.52</td><td align=\"left\">0.44</td><td align=\"left\">0.07\u20134.4</td><td align=\"left\">1.9<sup>i</sup>, 2.1<sup>sc</sup>, 2.2<sup>i</sup>, 4.4<sup>i</sup></td></tr><tr><td align=\"left\">S-alanine amintransferase (\u03bckat/L)</td><td align=\"left\">0.49</td><td align=\"left\">0.5</td><td align=\"left\">0.08\u20135.3</td><td align=\"left\">1.6<sup>i</sup>, 2.0<sup>i</sup>, 2.1<sup>sc</sup>, 5.3<sup>i</sup></td></tr><tr><td align=\"left\">S-alkaline phosphatase (\u03bckat/L)</td><td align=\"left\">1.3</td><td align=\"left\">6.7</td><td align=\"left\">1.0\u201364</td><td align=\"left\">12<sup>i</sup>, 12<sup>i</sup>, 14<sup>sc</sup>, 54<sup>i</sup>, 64<sup>i</sup></td></tr><tr><td align=\"left\">S-bilirubin (\u03bcmol/L)</td><td align=\"left\">14</td><td align=\"left\">25</td><td align=\"left\">3.0\u2013284</td><td align=\"left\">41<sup>sc</sup>, 88<sup>i</sup>, 284<sup>i</sup></td></tr></tbody></table></body></html>","text":"Pmid= 1079880:Table= Table 2","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-613699087,"_task_hash":680468322,"_session_id":null,"_view_id":"choice","accept":[3],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Inclusion and Exclusion Criteria</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Inclusion Criteria</bold></td></tr></thead><tbody><tr><td align=\"left\">\u2003\u2022 Males or non-pregnant, non-nursing females, age 18 to 65, with a DSM-IV diagnosis of alcohol dependence who express a desire to stop drinking.</td></tr><tr><td align=\"left\">\u2003\u2022 Heavy drinking (5 drinks/day for males or 4 drinks/day for females) within 14 days prior to randomization</td></tr><tr><td align=\"left\">\u2003\u2022 Able to achieve at least three continuous days of sobriety, without detoxification medications, immediately before beginning the oral naltrexone run-in dosing</td></tr><tr><td align=\"left\">\u2003\u2022 Willing and able to give informed consent</td></tr><tr><td align=\"left\">\u2003\u2022 Willing to practice effective birth control for duration of trial (female patients only)</td></tr><tr><td align=\"left\">\u2003\u2022 Available to participate in the study for 7 weeks</td></tr><tr><td align=\"left\">\u2003\u2022 Willing to provide names and permission to contact someone (e.g., spouse, parent, friend) who would likely know their whereabouts for follow-up tracking</td></tr><tr><td align=\"left\">\u2003\u2022 Naltrexone tolerance as demonstrated during run-in dosing period.</td></tr><tr><td colspan=\"1\"><hr/></td></tr><tr><td align=\"left\"><bold>Exclusion Criteria</bold></td></tr><tr><td colspan=\"1\"><hr/></td></tr><tr><td align=\"left\">\u2003\u2022 Currently taking disulfiram (Antabuse), naltrexone (Revia or generic) or neuroleptic medication</td></tr><tr><td align=\"left\">\u2003\u2022 In need of medical detoxification from alcohol</td></tr><tr><td align=\"left\">\u2003\u2022 DSM-IV diagnosis of dependence on any drug of abuse other than nicotine or alcohol or drug screen showing benzodiazepines, marijuana, cocaine, methamphetamine, barbituates or heroin</td></tr><tr><td align=\"left\">\u2003\u2022 Clinical evidence of cardiac ischemia (by EKG or medical history) or history of myocardial infarction within the previous 2 years</td></tr><tr><td align=\"left\">\u2003\u2022 History of pancreatitis</td></tr><tr><td align=\"left\">\u2003\u2022 Planned surgery within 7 weeks of screening</td></tr><tr><td align=\"left\">\u2003\u2022 Any chronic or episodic painful conditions that would reasonably require opiate medications for pain control</td></tr><tr><td align=\"left\">\u2003\u2022 ALT or AST elevations more than 3 times the upper limit of normal</td></tr><tr><td align=\"left\">\u2003\u2022 Subjects with any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation in the protocol.</td></tr><tr><td align=\"left\">\u2003\u2022 History of allergic or adverse response to naltrexone</td></tr><tr><td align=\"left\">\u2003\u2022 Participation in a trial of an investigational medication within 30 days prior to study enrollment</td></tr><tr><td align=\"left\">\u2003\u2022Subjects mandated by court for alcohol or drug abuse treatment or having pending legal proceedings that could result in incarceration within 7 weeks of screening</td></tr></tbody></table></body></html>","text":"Pmid= 1087493:Table= Table 1","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":1659506825,"_task_hash":-1420799327,"_session_id":null,"_view_id":"choice","accept":[2],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Baseline Demographic and Clinical Characteristics</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Characteristic</bold></td><td/></tr></thead><tbody><tr><td align=\"left\">Age in yr, mean (SD)</td><td align=\"center\">49.2 (13.4)</td></tr><tr><td align=\"left\">Gender, N (%)</td><td/></tr><tr><td align=\"left\">\u2003Male</td><td align=\"center\">13 (81.3)</td></tr><tr><td align=\"left\">\u2003Female</td><td align=\"center\">3 (18.8)</td></tr><tr><td align=\"left\">Ethnicity, N (%)</td><td/></tr><tr><td align=\"left\">\u2003Caucasian</td><td align=\"center\">10 (62.5)</td></tr><tr><td align=\"left\">\u2003Black</td><td align=\"center\">5 (31.3)</td></tr><tr><td align=\"left\">\u2003Hispanic</td><td align=\"center\">11 (6.3)</td></tr><tr><td align=\"left\">\u2003DSM-IV Alcohol Dependence Criteria Met, mean (SD)</td><td align=\"center\">5.4 (0.7)</td></tr><tr><td align=\"left\">Baseline Heavy Drinking Days, mean (SD)</td><td align=\"center\">10.9 (3.5)</td></tr><tr><td align=\"left\">Baseline Drinks Per Drinking Day, mean (SD)</td><td align=\"center\">8.4 (3.5)</td></tr><tr><td align=\"left\">Baseline Heavy Drinking Days, mean (SD)</td><td align=\"center\">8.1 (3.8)</td></tr></tbody></table></body></html>","text":"Pmid= 1087493:Table= Table 2","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-1426106975,"_task_hash":553080890,"_session_id":null,"_view_id":"choice","accept":[1],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Vital Signs and Liver Function Tests</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Parameter</bold></td><td align=\"center\"><bold>Pre-Treatment (= day -7) mean \u00b1 sd</bold></td><td align=\"center\"><bold>Post-Treatment (last visit) mean \u00b1 sd</bold></td></tr></thead><tbody><tr><td align=\"left\">Number of Patients</td><td align=\"center\">16</td><td align=\"center\">14</td></tr><tr><td align=\"left\">Systolic Blood Pressure, mm Hg</td><td align=\"center\">135 \u00b1 13</td><td align=\"center\">132 \u00b1 10</td></tr><tr><td align=\"left\">Diastolic Blood Pressure, mm Hg</td><td align=\"center\">85 \u00b1 9</td><td align=\"center\">83 \u00b1 6</td></tr><tr><td align=\"left\">Pulse, beats/min</td><td align=\"center\">80 \u00b1 5</td><td align=\"center\">79 \u00b1 9</td></tr><tr><td align=\"left\">AST, IU/L</td><td align=\"center\">31.9 \u00b1 14.6</td><td align=\"center\">27.6 \u00b1 22.7</td></tr><tr><td align=\"left\">Total Bilirubin, mg/dL</td><td align=\"center\">0.6 \u00b1 0.3</td><td align=\"center\">0.6 \u00b1 0.3</td></tr></tbody></table></body></html>","text":"Pmid= 1087493:Table= Table 3","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-909728605,"_task_hash":1500330931,"_session_id":null,"_view_id":"choice","accept":[1],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Adverse Injection Site Events</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>Adverse Event*</bold></td><td align=\"center\"><bold>Mild</bold></td><td align=\"center\"><bold>Moderate</bold></td><td align=\"center\"><bold>Severe</bold></td></tr></thead><tbody><tr><td align=\"left\">Bruising</td><td align=\"center\">2</td><td align=\"center\">0</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Inflammation</td><td align=\"center\">1</td><td align=\"center\">1</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Mass</td><td align=\"center\">3</td><td align=\"center\">3</td><td align=\"center\">1</td></tr><tr><td align=\"left\">Pain</td><td align=\"center\">3</td><td align=\"center\">6</td><td align=\"center\">1</td></tr><tr><td align=\"left\">Pigmentation Change</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">0</td></tr><tr><td align=\"left\">Site Reaction NOS</td><td align=\"center\">2</td><td align=\"center\">1</td><td align=\"center\">0</td></tr></tbody></table></body></html>","text":"Pmid= 1087493:Table= Table 4","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-462710927,"_task_hash":836101994,"_session_id":null,"_view_id":"choice","accept":[2],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Laboratory Value Abnormalities</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Adverse Event</bold></td><td align=\"center\"><bold>% Reporting Adverse Event</bold></td></tr></thead><tbody><tr><td align=\"left\">Blood Lactate Dehydrogenase Increased</td><td align=\"center\">31.3</td></tr><tr><td align=\"left\">Gamma-Glutamyl Transferase Increased</td><td align=\"center\">18.8</td></tr><tr><td align=\"left\">Red Blood Cells Present In Urine</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\">Proteinuria Present</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\">Alanine Aminotransferase Increased</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\">Blood Creatine Increased</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\">Hemoglobin Decreased</td><td align=\"center\">12.5</td></tr><tr><td align=\"left\">Hematocrit Decreased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Lymphocyte Count Decreased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Neutrophil Count Increased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Protein Total Increased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Aspartate Aminotransferase Increased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Uric Acid Increased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">Urine Analysis Abnormal NOS</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">White Blood Cell Count Increased</td><td align=\"center\">6.3</td></tr><tr><td align=\"left\">White Blood Cells In Urine</td><td align=\"center\">6.3</td></tr></tbody></table></body></html>","text":"Pmid= 1087493:Table= Table 5","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":1315900548,"_task_hash":-961780126,"_session_id":null,"_view_id":"choice","accept":[2],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Standard human PBPK organ weights, blood flows and fraction lipid</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Organ</bold></td><td align=\"left\"><bold>Weight (Kg)</bold></td><td align=\"left\"><bold>Fraction Lipid</bold></td><td align=\"left\"><bold>Perfusion (L/Kg)</bold></td><td align=\"left\"><bold>Total Flow (L/min)</bold></td></tr></thead><tbody><tr><td align=\"left\"><bold>Blood</bold></td><td align=\"right\">5.5</td><td align=\"right\">\u22480.01</td><td/><td/></tr><tr><td align=\"left\"><bold>liver</bold></td><td align=\"right\">1.8</td><td align=\"right\">0.25</td><td align=\"right\">0.25</td><td align=\"right\">0.45</td></tr><tr><td align=\"left\"><bold>portal</bold></td><td align=\"right\">1.5</td><td align=\"right\">0.02</td><td align=\"right\">0.75</td><td align=\"right\">1.125</td></tr><tr><td align=\"left\"><bold>muscle</bold></td><td align=\"right\">26</td><td align=\"right\">0.017</td><td align=\"right\">0.0225</td><td align=\"right\">0.585</td></tr><tr><td align=\"left\"><bold>kidney</bold></td><td align=\"right\">0.31</td><td align=\"right\">0.017</td><td align=\"right\">4</td><td align=\"right\">1.24</td></tr><tr><td align=\"left\"><bold>brain</bold></td><td align=\"right\">1.4</td><td align=\"right\">0.022</td><td align=\"right\">0.56</td><td align=\"right\">0.784</td></tr><tr><td align=\"left\"><bold>heart</bold></td><td align=\"right\">0.33</td><td align=\"right\">0.017</td><td align=\"right\">0.8</td><td align=\"right\">0.264</td></tr><tr><td align=\"left\"><bold>lung</bold></td><td align=\"right\">0.536</td><td align=\"right\">0.017</td><td align=\"right\">10.482</td><td align=\"right\">5.6184</td></tr><tr><td align=\"left\"><bold>skin</bold></td><td align=\"right\">2.6</td><td align=\"right\">0.017</td><td align=\"right\">0.1</td><td align=\"right\">0.26</td></tr><tr><td align=\"left\"><bold>tendon</bold></td><td align=\"right\">3</td><td align=\"right\">0.017</td><td align=\"right\">0.01</td><td align=\"right\">0.03</td></tr><tr><td align=\"left\"><bold>other</bold></td><td align=\"right\">5.524</td><td align=\"right\">0.017</td><td align=\"right\">0.02</td><td align=\"right\">0.1104</td></tr><tr><td align=\"left\"><bold>bone</bold></td><td align=\"right\">4</td><td align=\"right\">0</td><td align=\"right\">0</td><td align=\"right\">0</td></tr><tr><td align=\"left\"><bold>adipose</bold></td><td align=\"right\">17.5</td><td align=\"right\">0.8</td><td align=\"right\">0.0422</td><td align=\"right\">0.7385</td></tr><tr><td colspan=\"5\"><hr/></td></tr><tr><td align=\"left\"><bold>Total</bold></td><td align=\"right\">70</td><td/><td/><td align=\"right\">5.5877</td></tr></tbody></table></body></html>","text":"Pmid= 1090550:Table= Table 1","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":165606091,"_task_hash":-273473449,"_session_id":null,"_view_id":"choice","accept":[1],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Relationship between the intrinsic liver metabolic clearance (Tclr) and the fractional clearance of the total liver blood flow or the absolute steady state liver blood clearance for a standard male (20% fat, fraction free in plasma = 0.02).</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Tclr (liters/min)</bold></td><td align=\"left\"><bold>Fraction Liver Blood Flow</bold></td><td align=\"left\"><bold>Liver Clearance (liters/min)</bold></td></tr></thead><tbody><tr><td align=\"left\">10</td><td align=\"left\">0.13</td><td align=\"left\">0.23</td></tr><tr><td align=\"left\">50</td><td align=\"left\">0.47</td><td align=\"left\">0.846</td></tr><tr><td align=\"left\">100</td><td align=\"left\">0.68</td><td align=\"left\">1.224</td></tr><tr><td align=\"left\">200</td><td align=\"left\">0.86</td><td align=\"left\">1.548</td></tr><tr><td align=\"left\">300</td><td align=\"left\">0.93</td><td align=\"left\">1.674</td></tr><tr><td align=\"left\">400</td><td align=\"left\">0.962</td><td align=\"left\">1.731</td></tr><tr><td align=\"left\">500</td><td align=\"left\">0.977</td><td align=\"left\">1.76</td></tr></tbody></table></body></html>","text":"Pmid= 1090550:Table= Table 2","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-2066201206,"_task_hash":1804308260,"_session_id":null,"_view_id":"choice","accept":[3],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Comparison of the \"average weighted residual\" percent error for the PBPK model (this paper) and the 6 parameter NONMEM model of Schnider et. al. [20]. The PBPK model fits were for both the bolus and the constant infusion input phases, while the NONMEM model fit was for just the constant infusion phase. The PBPK model results are subdivided into the different age groups. The column labeled \"Individual Fits\" is the error when the model parameters were adjusted for each subject (see figs. 4\u20136). The column labeled \"Average Fits\" is the error when one parameter set with a linear age dependence for the fraction of pulmonary sequestration (eq. (13)) was used for all subjects (see figs. 9\u201311). The \"Average Fit\" error for the NONMEM model is listed for the case where the same set of 6 parameters were used for all subjects (\"No Covariates\") or an additional 5 covariate parameters (e.g. weight, height, age, etc) were used (\"Covariates\").</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"center\"><bold>PBPK Model Bolus + Infusion</bold></td><td align=\"left\"><bold>Age Group</bold></td><td align=\"left\"><bold>Individual Fits</bold></td><td align=\"left\"><bold>Average Fits</bold></td></tr></thead><tbody><tr><td/><td align=\"left\">18\u201334 years</td><td align=\"left\">13.5%</td><td align=\"left\">18.5%</td></tr><tr><td/><td align=\"left\">35\u201365 years</td><td align=\"left\">16.1%</td><td align=\"left\">23.8%</td></tr><tr><td/><td align=\"left\">&gt;65</td><td align=\"left\">15.4%</td><td align=\"left\">17.6%</td></tr><tr><td/><td><italic>Average</italic></td><td align=\"left\"><italic>15.0%</italic></td><td align=\"left\"><italic>20.0%</italic></td></tr><tr><td/><td/><td/><td/></tr><tr><td align=\"left\" colspan=\"2\">NONMEM Model Infusion Only [20]</td><td align=\"left\"><italic>14.18%</italic></td><td align=\"left\"><italic>23% </italic>No Covariates <italic>17.39% </italic>5 Covariates</td></tr></tbody></table></body></html>","text":"Pmid= 1090550:Table= Table 3","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":-764320085,"_task_hash":-2046861021,"_session_id":null,"_view_id":"choice","accept":[2],"answer":"accept"}
{"html":"<!DOCTYPE html><html><body><h4>Age dependence of steady state fractional liver blood flow clearance (Liver Clearance), the intrinsic liver clearance (Tclr), and fraction of bolus dose sequestered in lung (frdose).</h4><head><style> table, th, td {border: 1px solid black;}</style></head><body><table xmlns:xlink=\"http://www.w3.org/1999/xlink\" frame=\"hsides\" rules=\"groups\"><thead><tr><td align=\"left\"><bold>Age (years)</bold></td><td align=\"left\"><bold>Liver Clearance</bold></td><td align=\"left\"><bold>Tclr (liters/min)</bold></td><td align=\"left\"><bold>frdose</bold></td></tr></thead><tbody><tr><td align=\"right\">29.125</td><td align=\"right\">0.772</td><td align=\"right\">165</td><td align=\"right\">0.3</td></tr><tr><td align=\"right\">52.5</td><td align=\"right\">0.781</td><td align=\"right\">208</td><td align=\"right\">0.06875</td></tr><tr><td align=\"right\">74.75</td><td align=\"right\">0.762</td><td align=\"right\">104</td><td align=\"right\">0</td></tr></tbody></table></body></html>","text":"Pmid= 1090550:Table= Table 4","options":[{"id":0,"text":"PK Parameters"},{"id":1,"text":"Covariates"},{"id":2,"text":"Other"},{"id":3,"text":"Unclear"}],"_input_hash":674399580,"_task_hash":-462287745,"_session_id":null,"_view_id":"choice","accept":[2],"answer":"accept"}
